Connect Biopharma Holdings Ltd 8-K

What Happened

• On March 31, 2026, Connect Biopharma Holdings Limited announced its financial results for the fiscal year ended December 31, 2025 by issuing a press release that was filed on Form 8-K (Item 2.02). The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: March 31, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Fiscal year ended December 31, 2025.
• Press release attached as Exhibit 99.1; an Inline XBRL cover page (Exhibit 104) is included.
• The Form 8-K was signed by Lisa Peraza, Senior Vice President, Finance.

Why It Matters

• This 8-K formally notifies investors that Connect Biopharma reported its year-end financial results (earnings, revenue and related metrics) for FY2025; the press release is the first public source for those figures.
• Investors should review the attached press release and expect the company’s upcoming periodic filings (e.g., Form 10-K) for complete audited financial statements, detailed revenue, cash position, and management discussion that could affect valuation and investment decisions.